Blog

This is tagline here

Begbroke Science Park > News and Press > OGT announces operational and financial highlights for FY 2014
Please set your featured image

OGT announces operational and financial highlights for FY 2014

Oxford Gene Technology LogoFollowing its successful acquisition and integration of Cytocell Ltd, Oxford Gene Technology (OGT), the molecular genetics company, has provided an operational and financial update for the company’s financial year ended 30 September 2014. With total revenues up by 27% to £15.2m (FY2013: £11.9m), and commercial revenue growth of 54% to £11.9m (FY2013: £7.7m), Dr Mike Evans, CEO of OGT said:

“We have made some important operational decisions this year to help achieve our ambition to become a global leader in molecular genetics. A key component to our growth was the acquisition of Cytocell, and our R&D team has made significant progress on a number of high-value projects addressing the escalating NIPT and NGS markets, which will further fuel OGT’s growth. We expect to see continued momentum in the next financial year and beyond, building further value to our customers and the business.” read the full report here

Joanna Grant